Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

医学 帕妥珠单抗 内科学 曲妥珠单抗 临床终点 不利影响 肿瘤科 实体瘤疗效评价标准 贫血 队列 危险系数 癌症 进行性疾病 临床试验 置信区间 乳腺癌 疾病
作者
Timothy Lewis Cannon,Michael Rothe,Pam K. Mangat,Elizabeth Garrett‐Mayer,Vi K. Chiu,Jimmy J. Hwang,Namrata Vijayvergia,Olatunji B. Alese,Elie G. Dib,Herbert L. Duvivier,Kelsey Klute,Vaibhav Sahai,Eugene Ahn,Pablo M. Bedano,Deepti Behl,Sarah Sinclair,Ramya Thota,Walter J. Urba,Eddy S. Yang,Gina N. Grantham
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (27): 3228-3237 被引量:6
标识
DOI:10.1200/jco.23.02078
摘要

PURPOSE Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with ERBB2/3 amplification, overexpression, or mutation treated with pertuzumab plus trastuzumab are reported. METHODS Eligible patients had advanced BTC, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors with ERBB2/3 alterations, and a lack of standard treatment options. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16+ weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS Twenty-nine patients were enrolled from February 2017 to January 2022, and all had advanced BTC with an ERBB2/3 alteration. One patient was not evaluable for efficacy. One complete response, eight partial responses, and two SD16+ were observed for DC and OR rates of 40% (90% CI, 27 to 100) and 32% (95% CI, 16 to 52), respectively. The null hypothesis of 15% DC rate was rejected ( P = .0015). Four patients had at least one grade 3 adverse event (AE) or serious AE at least possibly related to treatment: anemia, diarrhea, infusion-related reaction, and fatigue. CONCLUSION Pertuzumab plus trastuzumab met prespecified criteria to declare a signal of activity in patients with BTC and ERBB2/3 amplification, overexpression, or mutation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
华仔应助欣慰的乌冬面采纳,获得10
刚刚
曹小仙男发布了新的文献求助10
2秒前
4秒前
张大泽同学发布了新的文献求助100
4秒前
5秒前
6秒前
大个应助小麦采纳,获得10
8秒前
ywl发布了新的文献求助10
8秒前
8秒前
9秒前
10秒前
飞翔的小鸟完成签到 ,获得积分10
10秒前
10秒前
11秒前
思源应助陈博文采纳,获得10
11秒前
伽拉发布了新的文献求助10
12秒前
学术蛔虫完成签到 ,获得积分10
12秒前
13秒前
林子完成签到,获得积分10
13秒前
澡雪发布了新的文献求助10
13秒前
13秒前
14秒前
123发布了新的文献求助10
14秒前
咪咪发布了新的文献求助10
14秒前
14秒前
15秒前
wtt发布了新的文献求助10
16秒前
16秒前
17秒前
小柒完成签到 ,获得积分10
18秒前
19秒前
chuyixiaohan发布了新的文献求助30
20秒前
林子发布了新的文献求助10
20秒前
20秒前
超级小子发布了新的文献求助10
20秒前
SciGPT应助咪咪采纳,获得10
22秒前
23秒前
12chow chow发布了新的文献求助10
24秒前
24秒前
gentleman完成签到,获得积分10
24秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975661
求助须知:如何正确求助?哪些是违规求助? 3520000
关于积分的说明 11200535
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798247
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390